EGFR and non-small cell lung carcinoma: In the JO25567 (A randomized phase 2 study comparing erlotinib and bevacizumab combination with erlotinib alone in NSCLC patients harboing EGFR mutaion) study, the median PFS was 9.7 months longer for patients with pleural or pericardial effusion treated with erlotinib plus bevacizumab than for patients treated with erlotinib alone (15.4 mo versus 5.7 mo; HR = 0.45 [95% CI: 0.25–0.82]).18